Flynn Pharma Ltd. stepped into the medical devices arena for the first time in 2012 with CollaGUARD. CollaGUARD is a translucent bioresorbable film comprising 100% type 1 collagen that has been developed by Innocoll using its proprietary CollaFilm technology.
CollaGUARD is used for the prevention of post operative adhesions in 34 territories including Europe, China, South East Asia, Canada and the Middle East.
About Postoperative Adhesions
Postoperative adhesions are abnormal fibrous connections that can form between any apposing internal organ and serous membraneas a natural consequence of abdominopelvic surgery. Adhesions occur in almost 95% of laparotomies and may lead to serious complications such as intestinal obstruction, secondary female infertility, and chronic abdominal or pelvic pain. More than 30% of patients who undergo open gynecologic or general surgery are readmitted within 10 years for disorders that are considered directly or potentially related to adhesions, with an average of 2 readmissions per patient. In the United States, there are approximately 350,000 hospitalizations annually for adhesiolysis following gynecologic or abdominal surgery, which account for almost 1 million inpatient days at a cost of $2.3 billion. Even for patients without complications, adhesions originating from a previous surgery can present significant surgical challenges and additional morbidity risks in subsequent operations.
For more information about CollaGUARD, please click here to visit the dedicated CollaGUARD website.